RU2017139094A - Вакцина - Google Patents
Вакцина Download PDFInfo
- Publication number
- RU2017139094A RU2017139094A RU2017139094A RU2017139094A RU2017139094A RU 2017139094 A RU2017139094 A RU 2017139094A RU 2017139094 A RU2017139094 A RU 2017139094A RU 2017139094 A RU2017139094 A RU 2017139094A RU 2017139094 A RU2017139094 A RU 2017139094A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- pcsk9
- vaccine according
- fragments
- sipwnlerit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (10)
1. Вакцина, включающая, по меньшей мере, два фрагмента пропротеинконвертазы субтилизин/кексин типа 9 (PCSK9), в которой первый фрагмент из указанных, по меньшей мере, двух фрагментов включает, по меньшей мере, 8 последовательных аминокислотных остатков из аминокислотных остатков с 150 по 170 из PCSK9 в соответствии с SEQ ID No. 9, и в которой, по меньшей мере, один фрагмент из указанных, по меньшей мере, двух фрагментов включает, по меньшей мере, 8 последовательных аминокислотных остатков с 205 по 225 из PCSK9 в соответствии с SEQ ID No. 9.
2. Вакцина по п.1, отличающаяся тем, что, по меньшей мере, два фрагмента выбирают из группы, состоящей из пептидов, имеющих аминокислотную последовательность SIPWNLERITPPR (SEQ ID No. 2), PEEDGTRFHRQASK (SEQ ID No. 3), PEEDGTRFHRQA (SEQ ID No. 4), EEDGTRFHRQASK (SEQ ID No. 5), EEDGTRFHRQAS (SEQ ID No. 6), SIPWNLERITP (SEQ ID No. 7) и SIPWNLERIT (SEQ ID No. 8).
3. Вакцина по п.1 или 2, отличающаяся тем, что, по меньшей мере, один фрагмент из PCSK9 имеет аминокислотную последовательность, которую выбирают из группы, состоящей из SIPWNLERITPPR (SEQ ID No. 2), SIPWNLERITP (SEQ ID No. 7) и SIPWNLERIT (SEQ ID No. 8) и, по меньшей мере, один фрагмент из PCSK9 имеет аминокислотную последовательность, которую выбирают из группы, состоящей из PEEDGTRFHRQASK (SEQ ID No. 3), PEEDGTRFHRQA (SEQ ID No. 4), EEDGTRFHRQASK (SEQ ID No. 5) и EEDGTRFHRQAS (SEQ ID No. 6).
4. Вакцина по любому из пп. 1-3, отличающаяся тем, что она включает SIPWNLERITPPR (SEQ ID No. 2) и PEEDGTRFHRQASK (SEQ ID No. 3), SIPWNLERITPPR (SEQ ID No. 2) и PEEDGTRFHRQA (SEQ ID No. 4), SIPWNLERITPPR (SEQ ID No. 2) и EEDGTRFHRQASK (SEQ ID No. 5), SIPWNLERITPPR (SEQ ID No. 2) и EEDGTRFHRQAS (SEQ ID No. 6), PEEDGTRFHRQASK (SEQ ID No. 3) и SIPWNLERITP (SEQ ID No. 7), PEEDGTRFHRQASK (SEQ ID No. 3) и SIPWNLERIT (SEQ ID No. 8), PEEDGTRFHRQA (SEQ ID No. 4) и SIPWNLERITP (SEQ ID No. 7), PEEDGTRFHRQA (SEQ ID No. 4) и SIPWNLERIT (SEQ ID No. 8), EEDGTRFHRQASK (SEQ ID No. 5) и SIPWNLERITP (SEQ ID No. 7), EEDGTRFHRQASK (SEQ ID No. 5) и SIPWNLERIT (SEQ ID No. 8), EEDGTRFHRQAS (SEQ ID No. 6) и SIPWNLERITP (SEQ ID No. 7) или EEDGTRFHRQAS (SEQ ID No. 6) и SIPWNLERIT (SEQ ID No. 8).
5. Вакцина по любому из пп. 1-4, отличающаяся тем, что, по меньшей мере, два фрагмента из PCSK9 включают остаток цистеина на C- и/или N-конце.
6. Вакцина по любому из пп. 1-5, отличающаяся тем, что, по меньшей мере, два фрагмента из PCSK9 соединены с фармацевтически приемлемым носителем, предпочтительно, с KLH (гемоцианин фиссуреллы).
7. Вакцина по любому из пп. 1-6, отличающаяся тем, что, по меньшей мере, два фрагмента из PCSK9 составлены в композицию для внутрикожного, подкожного или внутримышечного введения.
8. Вакцина по любому из пп. 1-7, отличающаяся тем, что она включает, по меньшей мере, один адъювант, предпочтительно, гидроксид алюминия.
9. Вакцина по любому из пп. 1-8 для применения при лечении и/или предупреждении нарушений, вызываемых гиперлипидемией, гиперхолестеринемией и/или атеросклерозом, предпочтительно, сердечно-сосудистых заболеваний, инсульта или заболеваний периферических сосудов.
10. Вакцина по п.9, отличающаяся тем, что, по меньшей мере, два фрагмента из PCSK9 вводят индивидууму в количестве, равном от 0,1 нг до 10 мг, предпочтительно, от 1 мкг до 500 мкг на дозу.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11181090.9A EP2570135B1 (en) | 2011-09-13 | 2011-09-13 | PCSK9 Vaccine |
EP11181090.9 | 2011-09-13 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014114506A Division RU2640258C2 (ru) | 2011-09-13 | 2012-09-13 | Вакцина |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2017139094A true RU2017139094A (ru) | 2019-02-12 |
RU2017139094A3 RU2017139094A3 (ru) | 2019-02-12 |
Family
ID=46851983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017139094A RU2017139094A (ru) | 2011-09-13 | 2012-09-13 | Вакцина |
RU2014114506A RU2640258C2 (ru) | 2011-09-13 | 2012-09-13 | Вакцина |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014114506A RU2640258C2 (ru) | 2011-09-13 | 2012-09-13 | Вакцина |
Country Status (24)
Country | Link |
---|---|
US (2) | US9220762B2 (ru) |
EP (2) | EP2570135B1 (ru) |
JP (1) | JP6054400B2 (ru) |
KR (1) | KR101983685B1 (ru) |
CN (1) | CN103874504B (ru) |
AU (1) | AU2012307348B8 (ru) |
BR (1) | BR112014005756A2 (ru) |
CA (1) | CA2848487A1 (ru) |
CY (2) | CY1117335T1 (ru) |
DK (2) | DK2570135T3 (ru) |
ES (2) | ES2565757T3 (ru) |
HR (2) | HRP20160392T1 (ru) |
HU (2) | HUE028583T2 (ru) |
IL (1) | IL231043A (ru) |
LT (1) | LT2755678T (ru) |
MX (1) | MX346883B (ru) |
PL (2) | PL2570135T3 (ru) |
PT (1) | PT2755678T (ru) |
RS (1) | RS54639B1 (ru) |
RU (2) | RU2017139094A (ru) |
SG (1) | SG11201400086QA (ru) |
SI (2) | SI2570135T1 (ru) |
SM (1) | SMT201600082B (ru) |
WO (1) | WO2013037889A2 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
WO2015123291A1 (en) * | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
MX2016010838A (es) * | 2014-02-28 | 2016-11-17 | Affiris Ag | Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). |
CN105085684B (zh) * | 2014-05-14 | 2020-04-17 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
MX2022009320A (es) * | 2020-01-28 | 2022-09-19 | United Biomedical Inc | Inmunógenos péptidos dirigidos a pcsk9 y formulaciones de los mismos para la prevención y el tratamiento de trastornos mediados por pcsk9. |
KR20210158693A (ko) * | 2020-06-24 | 2021-12-31 | 바이오스트림테크놀러지스(주) | 항 pcsk9 항체 및 이의 용도 |
JPWO2022244845A1 (ru) * | 2021-05-19 | 2022-11-24 | ||
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3249052B1 (en) * | 2006-05-11 | 2019-04-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the pcsk9 gene |
CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AT507604A1 (de) * | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Pcsk9 백신 |
-
2011
- 2011-09-13 DK DK11181090.9T patent/DK2570135T3/en active
- 2011-09-13 RS RS20160183A patent/RS54639B1/en unknown
- 2011-09-13 PL PL11181090T patent/PL2570135T3/pl unknown
- 2011-09-13 EP EP11181090.9A patent/EP2570135B1/en active Active
- 2011-09-13 ES ES11181090.9T patent/ES2565757T3/es active Active
- 2011-09-13 SI SI201130773A patent/SI2570135T1/sl unknown
- 2011-09-13 HU HUE11181090A patent/HUE028583T2/en unknown
-
2012
- 2012-09-13 BR BR112014005756A patent/BR112014005756A2/pt not_active Application Discontinuation
- 2012-09-13 EP EP12759427.3A patent/EP2755678B1/en active Active
- 2012-09-13 CA CA2848487A patent/CA2848487A1/en not_active Abandoned
- 2012-09-13 US US14/344,879 patent/US9220762B2/en not_active Expired - Fee Related
- 2012-09-13 LT LTEP12759427.3T patent/LT2755678T/lt unknown
- 2012-09-13 RU RU2017139094A patent/RU2017139094A/ru not_active Application Discontinuation
- 2012-09-13 PT PT127594273T patent/PT2755678T/pt unknown
- 2012-09-13 WO PCT/EP2012/067950 patent/WO2013037889A2/en active Application Filing
- 2012-09-13 HU HUE12759427A patent/HUE031860T2/en unknown
- 2012-09-13 SI SI201230903A patent/SI2755678T1/sl unknown
- 2012-09-13 MX MX2014002879A patent/MX346883B/es active IP Right Grant
- 2012-09-13 ES ES12759427.3T patent/ES2618796T3/es active Active
- 2012-09-13 PL PL12759427T patent/PL2755678T3/pl unknown
- 2012-09-13 RU RU2014114506A patent/RU2640258C2/ru not_active IP Right Cessation
- 2012-09-13 AU AU2012307348A patent/AU2012307348B8/en not_active Ceased
- 2012-09-13 SG SG11201400086QA patent/SG11201400086QA/en unknown
- 2012-09-13 DK DK12759427.3T patent/DK2755678T3/en active
- 2012-09-13 CN CN201280044571.4A patent/CN103874504B/zh not_active Expired - Fee Related
- 2012-09-13 JP JP2014530217A patent/JP6054400B2/ja not_active Expired - Fee Related
- 2012-09-13 KR KR1020147009735A patent/KR101983685B1/ko active IP Right Grant
-
2014
- 2014-02-19 IL IL231043A patent/IL231043A/en active IP Right Grant
-
2015
- 2015-10-23 US US14/921,485 patent/US9669079B2/en not_active Expired - Fee Related
-
2016
- 2016-03-22 SM SM201600082T patent/SMT201600082B/xx unknown
- 2016-03-31 CY CY20161100266T patent/CY1117335T1/el unknown
- 2016-04-15 HR HRP20160392TT patent/HRP20160392T1/hr unknown
-
2017
- 2017-02-27 HR HRP20170328TT patent/HRP20170328T1/hr unknown
- 2017-03-16 CY CY20171100333T patent/CY1118856T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017139094A (ru) | Вакцина | |
RU2014143531A (ru) | Вакцина против PCSK9 | |
RU2014112002A (ru) | Антигенные тау-пептиды и их применения | |
RU2016138365A (ru) | Pcsk9 вакцины | |
RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
JP2015110588A5 (ru) | ||
RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
RU2007145052A (ru) | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера | |
RU2015149387A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
RU2011100125A (ru) | Соединения для лечения амилоидозов | |
RU2012110582A (ru) | Применение мимеотопов альфа-синуклеиновых эпитопов для лечения заболеваний, связанных с тельцами леви | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
RU2013126888A (ru) | ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100 | |
RU2010110545A (ru) | Cdh3-пептид и включающее его лекарственное средство | |
RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
RU2008117328A (ru) | Иммуностимулирующая комбинация для профилактики и лечения гепатита с | |
RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
JP2012102105A5 (ru) | ||
RU2018120009A (ru) | Способ вакцинации против аутоантигена у пациента-человека | |
JP2018532782A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20200907 |